Cartesian Therapeutics, Inc. (RNAC) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RNAC Revenue Growth
Revenue Breakdown (FY 2025)
RNAC's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
RNAC Revenue Analysis (2014–2025)
As of May 8, 2026, Cartesian Therapeutics, Inc. (RNAC) generated trailing twelve-month (TTM) revenue of $1.8 million, reflecting significant decline in growth of -92.9% year-over-year. The most recent quarter (Q1 2026) recorded $78,000 in revenue, down 91.8% sequentially.
Looking at the longer-term picture, RNAC's 5-year compound annual growth rate (CAGR) stands at -30.0%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $110.8 million in 2022.
Revenue diversification analysis shows RNAC's business is primarily driven by Operating Segment (100%). With over half of revenue concentrated in Operating Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), ARQT (+95.3% YoY), and RCUS (+67.4% YoY), RNAC has underperformed the peer group in terms of revenue growth. Compare RNAC vs KYMR →
RNAC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RNACCurrent | $2M | -92.9% | -30.0% | -3099.9% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 ARQT | $376M | +95.3% | - | -3.3% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% |
RNAC Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.8M | -92.8% | $2.8M | 100.0% | $-86,705,000 | -3099.9% |
| 2024 | $38.9M | +49.6% | $38.9M | 100.0% | $-43,897,000 | -112.8% |
| 2023 | $26.0M | -76.5% | $26.0M | 100.0% | $-86,416,000 | -332.3% |
| 2022 | $110.8M | +30.2% | $108.7M | 98.2% | $14.5M | 13.1% |
| 2021 | $85.1M | +412.6% | $85.1M | 100.0% | $-4,597,000 | -5.4% |
| 2020 | $16.6M | +148.6% | $16.6M | 100.0% | $-56,821,000 | -342.4% |
| 2019 | $6.7M | +639.4% | $6.7M | 100.0% | $-52,455,000 | -785.6% |
| 2018 | $903K | +336.2% | $903K | 100.0% | $-65,022,000 | -7200.7% |
| 2017 | $207K | -97.4% | $207K | 100.0% | $-63,784,000 | -30813.5% |
| 2016 | $8.1M | +34.5% | $8.1M | 100.0% | $-34,670,000 | -428.9% |
See RNAC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RNAC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RNAC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRNAC — Frequently Asked Questions
Quick answers to the most common questions about buying RNAC stock.
Is RNAC's revenue growth accelerating or slowing?
RNAC revenue declined -92.9% year-over-year, contrasting with the 5-year CAGR of -30.0%. TTM revenue fell to $2M. This reverses the prior growth trend.
What is RNAC's long-term revenue growth rate?
Cartesian Therapeutics, Inc.'s 5-year revenue CAGR of -30.0% reflects the variable expansion pattern. Current YoY growth of -92.9% is below this long-term average.
How is RNAC's revenue distributed by segment?
RNAC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.